Isabel Mora, MD
Internal Medicine · East Orange, NJNPI 1972167682
Payments from drug & device makers
Across 208 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$573
- Bayer$364
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$361
- Boehringer Ingelheim$300
- Novo Nordisk$258
- Amgen$244
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,26299%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 42 | $573 |
| Bayer | 18 | $364 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $361 |
| Boehringer Ingelheim | 20 | $300 |
| Novo Nordisk | 19 | $258 |
| Amgen | 15 | $244 |
| Novartis | 13 | $232 |
| GSK | 11 | $187 |
| AstraZeneca | 10 | $184 |
| Pfizer | 7 | $116 |
| Merck | 5 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $57 |
| Hologic Sales And Service, LLC | 2 | $52 |
| Abbott | 3 | $52 |
| Madrigal Pharmaceuticals | 2 | $39 |
| AbbVie | 2 | $33 |
| Heartflow, Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$3,282 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 218 | $169,695 |
| FarxigaDapagliflozin Propanediol | 176 | $144,414 |
| RybelsusSemaglutide | 79 | $97,011 |
| OzempicSemaglutide | 89 | $93,311 |
| MounjaroTirzepatide | 84 | $92,246 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 65 | $73,525 |
| JardianceEmpagliflozin | 82 | $73,496 |
| EliquisApixaban | 86 | $69,606 |
| TrulicityDulaglutide | 50 | $67,884 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $65,181 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 80 | $64,390 |
| JanuviaSitagliptin Phosphate | 79 | $56,594 |
| JanumetSitagliptin Phos/Metformin Hcl | 68 | $54,002 |
| LinzessLinaclotide | 73 | $42,596 |
| SynjardyEmpagliflozin/Metformin Hcl | 44 | $33,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Trijardy Xr, Synjardy, Tradjenta | $300 | $294,221330 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $184 | $194,265298 claims |
| Novo NordiskRybelsus, Ozempic | $258 | $190,322168 claims |
| BayerKerendia | $364 | $169,695218 claims |
| Lilly USA, LLCMounjaro, Trulicity | $573 | $160,130134 claims |
| MerckJanuvia, Janumet, Janumet Xr | $75 | $126,944173 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $187 | $80,000131 claims |
| PfizerEliquis | $116 | $69,60686 claims |
| AbbVieLinzess | $33 | $42,59673 claims |
| NovartisEntresto | $232 | $26,16440 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $361 | $15,51924 claims |
| Johnson & JohnsonXarelto | $17 | $8,34812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in East Orange
- Darshi SunderamEast Orange$530K
- Alexander SalernoEast Orange$91K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.